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PhysiologicalactivationoftheN-methyl-D-aspartate(NMDA)subtypeofglutamatereceptorshasbeenproposedtoplayakeyrole
in both neuronal cell function and dysfunction. In the present study, we used selective NMDA receptor antagonists to investigate
the involvement of NR2A and NR2B subunits in the modulatory eﬀect of basal NMDA receptor activity on the phosphorylation
of Tau proteins. We observed, in acute hippocampal slice preparations, that blockade of NR2A-containing NMDA receptors by
the NR2A antagonist NVP-AAM077 provoked the hyperphosphorylation of a residue located in the proline-rich domain of Tau
(i.e., Ser199). This eﬀect seemed to be Ser199 speciﬁc as there was no increase in phosphorylation at Ser262 and Ser409 residues
located in the microtubule-binding and C-terminal domains of Tau proteins, respectively. From a mechanistic perspective, our
study revealed that blockade of NR2A-containing receptors inﬂuences Tau phosphorylation probably by increasing calcium inﬂux
into neurons, which seems to rely on accumulation of new NR1/NR2B receptors in neuronal membranes and could involve the
cyclin-dependent kinase 5 pathway.
1.Introduction
The N-methyl-D-aspartate (NMDA) subtype of ionotropic
glutamate receptors is known to play essential roles in the
mammalian central nervous system [1–3]. For instance, in
several pathological circumstances associated with neuronal
damage, excessive levels of calcium inﬂux through NMDA
receptor channels are well recognized to promote cell death
mechanisms, such as excitotoxicity and apoptosis [4, 5].
Over the years, however, a growing number of reports have
revealedthat,incontrasttothedestructiveeﬀectsofexcessive
NMDA receptor activity, synaptic NMDA receptor stimu-
lation under physiological conditions could result in the
activation of prosurvival mechanisms [6–9]. Along this line,
tonicactivationofNMDAreceptorsinhippocampalneurons
was demonstrated to be important in maintaining synaptic
stability, through a mechanism involving modulation of
dendritic protein synthesis. In fact, it has been reported
that tonic NMDA receptor activation acts as a crucial
mechanism regulating calcium mobilization in neurons, as
NMDA receptor deprivation rapidly increases the synaptic
expression of surface GluR1 subunits and the incorporation
of Ca2+-permeable AMPA receptors at synapses [10].
Therearealsoseveralindications thatphysiologicallevels
of NMDA receptor activation could play an active role in
regulating cytoskeleton integrity and function. For example,
arecentstudybyFiumellietal.[11]revealedthatsuppression
of NMDA receptor activity by global antagonists (MK801 or
AP5) can interfere with both phosphorylation and solubility
of neuroﬁlament subunit M in isolated cortical neurons.
In this particular case, neurite outgrowth is promoted by
the inactivation of NMDA receptors, suggesting that basal
levels of NMDA receptor activity are crucial for regulating
cytoskeleton stability and growth processes. Some authors
have reported that tonic NMDA receptor activity in cere-
bellar granule cells and hippocampal neurons also regulates
microtubule-associated protein 2 (MAP2) phosphorylation
and neurite growth in the cerebellum [12, 13], while others
have shown that activation of NMDA receptors in physio-
logical conditions is likely to inﬂuence Tau phosphorylation
in the hippocampal area [11, 14]. Tau proteins are well
known for their involvement in the outgrowth of neural2 Neural Plasticity
processes, the development of neuronal polarity, and the
maintenance of normal neuron morphology [15]. Several
investigations have demonstrated that disruption of normal
Tau phosphorylation could be a key factor contributing
to neurodegenerative disorders such as Alzheimer’s disease
(AD) [16–18].
Although the detailed molecular mechanisms by which
NMDA receptors can regulate both physiological and patho-
physiological processes remain to be elucidated, it has been
proposed that NMDA receptors function may be highly
dependent on the composition of their subunits, which
are heteromeric assemblies of at least 1 NR1 subunit and
various NR2 (A-D) subunits [19–21]. In the hippocampus,
extensive evidence indicates that, in the mature stage,
pyramidal cells mainly express NMDA receptors containing
NR1/NR2AandNR1/NR2Bsubunits[22].Fromafunctional
perspective, it has been argued by many that NR1/NR2A
subunit activation could favour the action of prosurvival
mechanisms, whereas NR1/NR2B subunit stimulation could
lead to neuronal cell death by the involvement of various
damaging signalling pathways [23, 24]. Accordingly, using
diﬀerent pharmacological agents, we observed that the
tonic stimulation of NR2A-containing NMDA receptors in
acute hippocampal slices might be a crucial component
inﬂuencing Tau phosphorylation.
2.MaterialsandMethods
2.1. Ethics Approval. Animal care procedures were reviewed
bytheInstitutionalAnimalCareCommitteeoftheUniversit´ e
du Qu´ ebec ` a Trois-Rivi` eres and found to be in compliance
with guidelines of the Canadian Council on Animal Care.
2.2. Animals and Pharmacological Agents. Male Sprague-
Dawley rats (6-7 weeks of age), purchased from Charles
River Laboratories (Montr´ eal, QC, Canada), were housed
for 1 week prior to any experiments in a temperature-
controlled room, with free access to laboratory chow and
water. The selective NR2A antagonist NVP-AAM077 (NVP)
was a gift from Dr. Yves Auberson (Novartis Pharma
AG, Basel, Switzerland). NR2B (RO25-6981) and AMPA
(NBQX) receptor antagonists were obtained from Tocris
Bioscience (Ellisville, MO, USA), while the glycogen syn-
thase kinase-3 beta (GSK-3β) inhibitor SB-216367 was pro-
cured from BioMol (Plymouth, PA, USA). Cyclin-dependent
kinase 5 (roscovitine), calpain (calpeptin) as well as pro-
tease and phosphatase inhibitor cocktails were acquired
from Calbiochem (San Diego, CA, USA). The membrane-
impermeable and the membrane-permeable calcium chela-
tor BAPTA were purchased from BioMol (Plymouth, PA,
USA). The biotinylation reagent Sulfo-NHS-SS-Biotin was
bought from Fisher Scientiﬁc (Nepean, ON, Canada). All
other chemicals were supplied by Sigma-Alrich (Oakville,
ON, Canada).
2.3. Antibodies. Most antibodies reacting with Tau proteins
were purchased from AbCam (Cambridge, MA, USA). The
mouse polyclonal antibody Tau-5 was used (dilution 1:500)
to estimate the total levels of Tau proteins in hippocampal
extracts, along with rabbit polyclonal antibodies recognizing
Tau phosphorylated at Ser199 (dilution 1:1,000), Ser262
(dilution 1:1,000), and Ser409 (dilution 1:1,000). GAPDH
antibody also was purchased from AbCam, and rabbit poly-
clonal antibodies against NR1—(dilution 1:200), NR2A—
(dilution 1:200), and NR2B-containing (dilution 1:200)
NMDA receptors were obtained from Santa Cruz Biotech-
nology (San Diego, CA, USA). Rabbit anti-GluR1 (dilution
1:20) was provided by Calbiochem. Goat antirabbit or
goat antimouse peroxydase-conjugated antibodies (dilution
1:5,000) and SuperSignal chemiluminescent substrate kits
were from Pierce Chemical Co. (Rockford, IL, USA).
2.4. Hippocampal Slices and Tissue Samples. Sprague-Dawley
ratswereanesthetizedbyisoﬂuraneinhalation(BaxterCorp.,
Toronto, ON, Canada) and decapitated. Their brains were
quicklyremovedandplacedincoldcuttingbuﬀercontaining
126mM NaCl, 3.5mM KCl, 1.2mM NaH2PO4,2 . 3 m M
MgCl2,1m MC a C l 2,2 5m MN a H C O 3, and 11mM glucose,
saturated with 95% O2/5% CO2 (pH 7.4). Coronal brain
sections of 350μm containing the hippocampus were sliced
in a Vibratome Series 1000 tissue sectioning system (Techni-
calproductsinternationalInc.,St.Louis,MO,USA).Sections
were then transferred to artiﬁcial cerebrospinal ﬂuid (ACSF)
containing 126mM NaCl, 3.5mM KCl, 1.2mM NaH2PO4,
1.3mM MgCl2,2m MC a C l 2,2 5m MN a H C O 3,a n d1 1m M
glucose, bubbled continuously with 95% O2/5% CO2 at
32◦C. The brain sections were preincubated for 60 minutes
before pharmacological treatment. After pharmacological
treatment, hippocampal slices were dissected from the brain
sections and homogenized in ice-cold RIPA lysis buﬀer con-
taining 50mM Tris-HCl, 150mM NaCl, 1% Triton X-100,
0.25%sodiumdeoxycholate,and1mMEDTAsupplemented
with protease and phosphatase inhibitor cocktails.
2.5. Cell Surface Biotinylation. Hippocampal slices were
incubated for 2 hours with or without NVP-AAM0077.
After several washes with ACSF bubbled constantly with
95% O2/5% CO2, each hippocampal slice was incu-
bated in 1mg/ml sulfosuccinimidyl-2-(biotinamido) ethyl-
dithiopropionate (sulfo-NHS-SS-biotin), followed by sev-
eral washes with sulfo-NHS-SS-biotin blocking reagent
(50mM NH4Cl in PBS containing 1mM MgCl2 and 0.1mM
CaCl2)a t4 ◦C to quench free sulfo-NHS-SS-biotin, fol-
lowed by more than a few washes in ACSF at 4◦C. Each
slice was homogenized in 100μlo fT r i sa c e t a t eb u ﬀer
(50mM, pH 7.4) containing 1mM EGTA, 1mM EDTA,
and numerous protease and phosphatase inhibitors (leu-
peptin10μM, phenylmethylsulfonyl ﬂuoride 1μg/ml, and
N-tosyl-L-phenylalanine chloromethyl ketone 1μg/ml). The
samples were centrifuged for 10 minutes at 11,070rpm at
4◦C. The supernatants were removed and the pellets were
suspended in fresh, ice-cold Tris acetate buﬀer. Streptavidin
beads (50μl/300μg of proteins) were washed 3 times with
Tris acetate buﬀer. Biotinylated samples (300μg of protein)
wereaddedtothebeadsandmixedatroomtemperaturefor4
hours. The beads were recovered by brief centrifugation, andNeural Plasticity 3
the supernatants were removed. The beads were washed 3
t i m e sw i t hT r i sa c e t a t eb u ﬀer, and biotinylated samples were
eluted from the beads with 4 X sodium dodecyl sulphate-
10% polyacrylamide gel electrophoresis (SDS-PAGE) load-
ing buﬀer (containing β-mercapto-ethanol) at 100
◦Cf o r1 0
minutes. The supernatants were removed, and biotinylated
protein levels were detected by SDS-PAGE and immunoblot-
ting.
2.6. Western Blotting. Protein levels extracted from rat
hippocampus sections were measured by Bradford assay
(Bio-Rad, Hercules, CA, USA). Electrophoresis of protein
lysates (40μg), except for the NR2B subunits which required
80μg of homogenized protein, was performed on 10%
polyacrylamide gel (SDS-PAGE). Separated proteins were
transferred onto nitrocellulose membranes and nonspeciﬁc
binding sites were blocked by incubation for 1 hour at
room temperature in phosphate-buﬀered saline, pH 7.4,
containing 5% bovine serum albumin (BSA fraction V)
purchased from Fisher Scientiﬁc (Pittsburgh, PA, USA).
Then, selected primary antibodies were incubated overnight
at 4◦C. After several washes with 0.1% Tween 20, the
blots were incubated for 2 hours at room temperature in
speciﬁc secondary HRP-conjugated antibody solution. Both
primary and secondary antibodies were diluted in TBS/0.1%
Tween 20/1% BSA. Immunoreactivity was visualized by
chemiluminescence reactions, and the intensity of the bands
was quantiﬁed by densitometric scanning through Vision
WorkLSsoftware(UVPBioimaging,Upland,CA,USA).The
densitometry data were expressed as relative optical density.
2.7. Statistical Analysis. The results are expressed as mean
average ± SEM. Statistical signiﬁcance of the changes was
determined using Graph Prism version 5.0 (Graph Pad
Software, San Diego, CA, USA). P<. 05 values were
considered as statistically signiﬁcant.
3. Results
3.1. Blockade of NR2A-Containing NMDA Receptors Selec-
tively Enhances Phosphorylation of Tau Proteins at Ser199
Residues. In this study, we investigated the inﬂuence of tonic
NMDA receptor activity on Tau status by quantifying phos-
phorylation and protein levels in the hippocampus. Acute
hippocampal slices from rats were treated for diﬀerent time
periodswithNMDAreceptorantagonistsandthenprocessed
by Western blotting. We ﬁrst examined Tau phosphorylation
levels on Ser199 after preincubating hippocampal slices with
NVP-AAM077 (NVP) and R025-6981 (RO), 2 compounds
that preferentially block, respectively, NR2A- and NR2B-
containing NMDA receptors. Our experiments were per-
formed with 50nM NVP and 1μM RO, concentrations that
are known to be highly selective for NR2A and NR2B,
respectively [25, 26]. In initial experiments, we observed that
hippocampal tissues were strongly and consistently stained
with an antibody recognizing the phosphorylated Ser199
epitope of a Tau isoform estimated to 62kDa (Figure 1,t o p
panels). As presented in the Figure 1 histogram, we observed
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Figure 1: Blockade of NR2A-containing NMDA receptors induces
Tau phosphorylation at Ser199 site in rat hippocampal slices.
Phosphorylation and protein levels were estimated by Western
blotting on cell extracts (40μg proteins) obtained from acute
hippocampal slices treated with 2NMDA receptor antagonists for
periods ranging from 1 to 3 hours. Phosphorylated Tau levels at
Ser199,expressed relativetototal Tau(Tau-5)levels,weremeasured
in slices treated with 50nM NVP and 1μMR O .T h ed a t aw e r e
expressed as percentage of control values and are means ± SEM
of 3 measurements per cell extract obtained from 7 diﬀerent rats.
Statistical analysis using two-way ANOVA followed by the post
hoc Bonferroni test revealed that there was a main eﬀect between
treatment (F(2,54) = 16.370, P<. 0001), no eﬀect between time
(F(2,54) = 2.509, P = .091) and no signiﬁcant interaction between
treatment and time (F(4,54) = 1.337, P = .268). ∗P<. 05, ∗∗∗P<
.001, drug-treated versus control.
that this Tau isoform became progressively hyperphospho-
rylated at the Ser199 residue after blockade of NR2A-
containing NMDA receptors with NVP (Figure 1,b l a c k
bars). In fact, when normalized with Tau-5 (an antibody
that recognized phosphate-independent epitopes of Tau), it
became evident that overtime NVP elevated phosphorylated
TaulevelsatitsSer199site,withamaximalincreaseobserved
in slices preincubated for a period of 2 hours (n = 5, P<
.01). Time-course analysis showed, however, that Ser199 was
not subjected to substantial change in phosphorylation after
exposure to the NR2B antagonist RO (Figure 1, grey bars).
It is noteworthy that treatments of rat hippocampal slices
with both NVP and RO failed to produce signiﬁcant changes
in Tau-5 staining intensity (Figure 1, top panels), indicating
that Ser199 hyperphosphorylation resulting from blockade
ofNR2A-containingreceptorsisnotdependentonvariations
in Tau synthesis and/or degradation.
So far, Tau has been found to possess 70 diﬀerent
phosphorylation sites. The Ser199 epitope is known to
be located in the proline-rich domain of Tau proteins.4 Neural Plasticity
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Figure 2: Blockade of NR2A-containing NMDA receptors is not
associated with increased Tau phosphorylation levels at Ser409 and
Ser262 sites. Phosphorylation and protein levels were estimated by
Western blotting on cell extracts (40μg proteins) obtained from
acute hippocampal slices treated with 50nM NVP for 2 hours.
Phosphorylated Tau levels, expressed relative to total Tau (i.e.,
Tau-5) levels, were measured using antibodies raised against Tau
phosphorylated at Ser199, Ser262, and Ser409. The data were
expressed as percentage of control values and are means ± SEM of 3
measurements per cell extract obtained from 6 diﬀerent rats. Since
these experiments were independently performed, we determined
statistical signiﬁcance using unpaired T-Test. ∗P<. 05, ∗∗∗P<
.0001, NVP-treated versus control.
This observation led us to investigate whether other Tau
phosphorylation sites are also under the inﬂuence of NMDA
receptors containing NR1/NR2A subunits. Figure 2 shows
that preincubation of hippocampal slices with NVP (50nM
for 2 hours) failed to elicit any changes in phosphorylation
at the Ser409 residue of Tau proteins, a phosphorylation
site positioned in the C-terminal domain. Similarly, Western
blotting experiments indicated that phosphorylation of an
epitope located in the microtubule-binding domain of Tau
(Ser262) was not accentuated after blockade of NR2A-
containing NMDA receptors. If anything, quantiﬁcation and
averaging of data obtained from several slices indicated
that, in contrast to Ser199, after 2-hour NVP exposure,
phosphorylated Ser262 levels were slightly but signiﬁcantly
reduced (Figure 2).
3.2. Role of Calcium and Cdk5 Signalling in NVP-Induced
Tau Phosphorylation. Previous studies in rat hippocampal
cultures indicated that NMDA receptor antagonists, such as
MK801, rapidly increased calcium permeability in neurons
[10]. Thus, we sought to investigate whether NVP-induced
phosphorylation might, in fact, be dependent on calcium
mobilization. We observed that preexposure of hippocampal
slices to BAPTA-AM, a cell-permeable agent with very high
aﬃnityforcalcium,completelyabolishedtheincreasedlevels
of phosphorylated Tau at its Ser199 residue (Figure 3(a)).
Similarly, preexposure of hippocampal slices to the cell-
impermeable form of BAPTA also completely blocked
the NVP-induced phosphorylation of Ser199 (Figure 3(a)),
indicating that Tau hyperphosphorylation after inhibition
of NR2A-containing receptors mainly relies on calcium
entrance from the extracellular space.
The observation that the eﬀect of NVP is dependent on
calcium entrance predicts that selective phosphorylation at
Ser199 residue could involve the action of protein kinases.
The proline-directed protein kinases known to inﬂuence
phosphorylation of Ser199 residue include GSK-3β and
Cdk5(Figure 3(b)).Therefore,basedonthisinformation,we
examined whether inhibitors of Cdk5 or GSK-3β signalling
pathways might prevent NVP-induced phosphorylation at
the Ser199 site. To assess a possible role of GSK-3β in Tau
phosphorylation induced by blockade of NR2A-contaning
receptors, we used the selective GSK-3β inhibitor SB216367.
In these experiments, the inhibitor was applied 45 minutes
before NVP exposure to ensure optimal inhibition of GSK-
3β. We observed that preexposure of slices to 10μMo f
SB216367 did not interfere with NVP-induced phosphory-
lation. On the contrary, Ser199 hyperphosphorylation in
slices preexposed to 10μM roscovitine was totally prevented;
indicating that NVP-induced Tau phosphorylation at Ser199
primarily involves the Cdk5 pathway. We also evaluated
whether calpain-mediated activation of Cdk5 could be
responsible for the eﬀects on Tau phosphorylation. Here,
calpeptin did not prevent NVP-induced Tau phosphoryla-
tion, suggesting that this phenomenon occurs independently
of calpain activation (Figure 3(b)).
3.3. NVP-Induced Tau Phosphorylation Relies on Activation
of NR2B-Containing NMDA Receptors. Taken together, the
above ﬁndings indicate that blockade of NR2A-containing
NMDA receptors promotes Tau phosphorylation at Ser199
residue, implicating both calcium and the Cdk5 signalling
pathway. The exact mechanisms by which NVP induces
calcium mobilization, however, remain to be clariﬁed. One
possibility is that blockade of NR2A-containing NMDA
receptors could have led to calcium entrance in neurons
by favouring the dysregulation of other glutamate receptor
subtypes. Thus, we initiated a series of experiments to
determine the eﬀects of glutamate receptor antagonisms
on NVP-induced Tau phosphorylation in rat hippocampal
slices.Here,wereporttheresultsobtainedwithanantagonist
acting on the AMPA subtype of glutamate receptors (NBQX)
and the antagonist acting on NR2B-containing NMDA
receptors (i.e., RO). Figure 4 shows that preexposure of
hippocampal slices to 10μM NBQX did not signiﬁcantly
reduce Tau phosphorylation at Ser199 residue resulting from
inhibition of NR2A-containing receptors by NVP. However,
NVP-induced Tau phosphorylation was completely reversed
by the preincubation of slices in the presence of RO, sug-
gesting that the ability of NVP to enhance phosphorylation
of the Ser199 epitope is possibly dependent on alterations
of NR2B-containing NMDA receptors. Indeed, we decided
to test this scenario by measuring the surface expression of
both AMPA and NMDA receptor subunits on biotinylated
membranes [27]. As shown in Figure 5(a), the surface level
of GluR1 subunits of AMPA receptors was not signiﬁcantly
modiﬁed in slices treated with NVP. In contrast, a signiﬁcant
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Figure 3: NVP-induced Tau phosphorylation is mediated by calcium and the Cdk5 pathway. (a) Phosphorylated Tau levels at Ser199 were
estimated by Western blotting on cell extracts obtained from acute hippocampal slices treated with 50nM NVP for 2 hours alone or in
combination with 10μM BAPTA-AM or 10μM BAPTA. The data are expressed relative to total Tau (i.e., Tau-5) levels. (b) As in A, except for
theGSK-3β inhibitorSB216367(10μM),theCdk5inhibitorroscovitine(10μM),orthecalpaininhibitorcalpeptine(10μM)wereemployed.
The data were expressed as percentage of control values and are means ± SEM of 3 measurements per cell extract obtained from 5 diﬀerent
rats. Statistical analysis was performed by one-way ANOVA followed by Neuman-Keuls’ post hoc test. ∗∗∗P<. 001, drug-treated versus
control.
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Figure 4: NR2B-containing receptors play a role in Tau phospho-
rylation induced by NVP. Phosphorylated Tau levels at Ser199 were
estimated by Western blotting on cell extracts obtained from acute
hippocampal slices treated with 50nM NVP for 2 hours alone or in
combination with 10μMN B Q Xa n d1 0μM RO25-6981. The data,
expressed relative to total Tau (i.e., Tau-5) levels, are means ± SEM
of 3 measurements per cell extract obtained from 4 diﬀerent rats.
Statistical analysis was performed by one-way ANOVA followed by
Neuman-Keuls’ post hoc test. ∗P<. 05, ∗∗∗P<. 001, drug-treated
versus control.
hippocampal slices 2 hours after NVP exposure. The NR2A
antagonist was found to increase NR1 subunit levels by
more than 60% in biotinylated membranes prepared from
hippocampal slices (Figure 5(b)), while similar results were
obtained with NR2B subunit levels (Figure 5(c)).
4. Discussion
In this study, we examined the eﬀects of inhibition of
NR2A- and NR2B-containing NMDA receptors on Tau
phosphorylation in acute hippocampal slices. We demon-
strated that pharmacological blockade of NR2A-containing
NMDA receptors induces a robust and selective increase
of the phosphorylation level of the serine residue Ser199
of Tau. Moreover, we showed that calcium mobilization
and activation of the Cdk5 signalling pathway are directly
involved in this eﬀect, which probably rely on the insertion
of new NR1/NR2B subunits in neuronal membranes. A
putative biochemical model that accounts for the control of
Tau phosphorylation by NVP is illustrated in Figure 6.
According to our results, inactivation of NR2A-
containing NMDA receptors by NVP in acute hippocampal
slices elicits a signiﬁcant increase in the phosphorylation
state of Tau, suggesting that the tonic activity of these
receptors contributes to limit Tau phosphorylation in basal
physiological conditions. This is in line with previous
in vitro studies showing that suppression of NMDA
receptor activity by global antagonists (MK801 or AP5) can6 Neural Plasticity
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Figure 5: Blockade of NR2A-containing NMDA receptors is associated with increased levels of NR1 and NR2B subunits in biotinylated
membranes. Glutamate receptor subunit levels were estimated by Western blotting on biotinylated membranes obtained from acute
hippocampal slices treated with 50nM NVP for 2 hours. Biotinylated NR1, NR2B and GluR1 subunit levels were normalized with respective
total protein levels estimated in homogenates of hippocampal slices incubated with or without NVP. The data are means ± SEM of 3
measurements obtained from 4 diﬀerent rats. Since these experiments were independently performed, we determined statistical signiﬁcance
using unpaired T-Test. ∗∗P<. 01, ∗∗∗P<. 001, NVP-treated versus control.
enhance Tau phosphorylation [11]. In the present report,
we demonstrate that hyperphosphorylation of Ser199
residue resulting from inactivation of NR2A-containing
NMDA receptors is totally abrogated by the nonpermeable
form of BAPTA, indicating that the eﬀect likely relies on
calcium entry into neuronal cells. In this context, we have
investigated the potential signalling pathways underlying
NVP-induced tau phosphorylation in hippocampal slice
preparations. The phosphorylation state of Tau epitopes
is known to be under the regulation of various kinase
pathways, which are directly or indirectly inﬂuenced by
calcium ions. Generally, Tau is phosphorylated by 2 major
categories of kinases, which are divided according to
motif speciﬁcity: proline-directed protein kinases (PDPK)
and nonproline-directed protein kinases (non-PDPK)
[28]. Cdk5, mitogen-activated protein kinase, and several
stress-activated protein kinases are included in the PDPK
family. GSK-3β is habitually described as a PDPK, although
proline is not always necessary for Tau phosphorylation
by GSK-3β. Non-PDPK include cyclic AMP-dependent
protein kinase A, calcium- and calmodulin-dependent
protein kinase II, and microtubule aﬃnity regulating kinase
(MARK), the mammalian homologue of PAR-1 present in
Drosophila [29]. MARK selectively phosphorylates a KXGS
motif, within the microtubule binding repeat domains of
Tau (serine residues at 262, 293, 324, and 356) [28]. The
present data show that blockade of NR2A subunits with
NVP signiﬁcantly increased the phosphorylation of Ser199
epitope located in the proline-rich domain of Tau. From a
mechanistic perspective, we demonstrated that this eﬀect is
possibly not dependent on GSK-3β activity, since blockade
of the system by SB216367 had no eﬀect on NVP-induced
phosphorylationatSer199residue.However,applicationofa
speciﬁc inhibitor of the Cdk5 pathway completely abolished
NVP-induced Tau phosphorylation at Ser199 residue.
Indeed, we have yet to fully characterize the mechanism
by which Cdk5 enhances Tau phosphorylation at Ser199
but,accordingtothe presentinvestigation, this phenomenonNeural Plasticity 7
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Figure 6: Working model of NVP-induced Tau phosphorylation. Blockade of NR2A-containing receptors appears to initiate the insertion
of new functional NMDA receptors containing a high proportion of NR2B subunits in neuronal plasma membranes, promoting calcium
accumulation. Through an unknown mechanism, Cdk5 activity would selectively enhance the phosphorylation of Ser199 residue in the
proline-rich domain of Tau. In parallel, blockade of NR2A-containing receptors may reduce speciﬁc phosphatase activity which could have
an impact on Tau phosphorylation at Ser199.
appears to be independent of the activation of calpain
enzymes, which are known to favour intracellular accumu-
lation of the potent p25 activator of Cdk5 [30, 31]. In this
line, our ﬁndings imply that other Cdk5 activators might be
involvedintheabove-mentioned eﬀectsofNVPonTau.This
hypothesis is strongly supported by recent studies showing
that Cdk5 activation can depend on IC53 production, a
new potential activator of this kinase system [32]. In terms
of cellular distribution, there are several indications that
Tau proteins mainly localised in axonal compartments of
neurons. Predictably, because of the preferential localization
of NR2A-containing receptors in synapses, our ﬁndings
implicate potential biochemical links between a presumable
increase in dendritic calcium and subsequent stimulation
of axonal Cdk5 in neurons subjected to NMDA receptor
deprivation. However, as Tau proteins are also known to be
localized in somatodendritic compartments of neurons, our
results highlighted the need to also explore the possibility
that NR2A-containing NMDA receptors could diﬀerentially
inﬂuence Tau phosphorylation in axonal and somatoden-
dritic compartments of neurons.
There are several lines of evidence that phosphory-
lation of other cytoskeletal proteins is accentuated after
inhibition of NMDA receptors [11, 13]. For instance, it
has been proposed that tonic NMDA receptor activation
plays an essential role in limiting MAP2 phosphorylation
in hippocampal slices through a mechanism involving
stimulation of the calcium/calmodulin-dependent protein
phosphatase calcineurin [13, 14]. Accordingly, one can
speculate that the eﬀect reported here would be dependent
on inhibition of phosphatase activities after the blockade
of NR2A-containing NMDA receptors by NVP. However,
although this antagonist was found to markedly enhance
the phosphorylation of Ser199 residue, it did not similarly
augment the phosphorylation of other residues located
in both the C-terminal (Ser409) and microtubule-binding
(Ser262) domains of Tau, suggesting that dephosphorylation
processes are not impaired by the blockade of NR2A-
containing receptors. Nevertheless, it is worth mentioning
that according to previous studies, Ser199 residues might
represent unusual phosphorylation sites of Tau as they
appeartobeinﬂuencedbyaveryspeciﬁctypeofphosphatase
activity (i.e., PP5) [33]. Indeed, experiments are required
to directly examine whether inhibition of NR2A-containing
receptors could lead to preferential reduction of PP5 activity
in hippocampal slices. Independently of the mechanisms
involved, the current study reinforces the recent observa-
tion that the serine residues of Tau can be diﬀerentially
modulated in diverse circumstances. Along this line, by
interferingwithPLA2activityinembryonicrathippocampal
neurons, De-Paula et al. [34] observed that Tau proteins may
become hyperphosphorylated on Ser214 residue, sparing
other epitopes, including Ser199, Ser202, Ser205, and Ser396
phosphorylation sites.8 Neural Plasticity
The biochemical demonstration that NVP-induced Tau
phosphorylation is completely abolished by preexposure of
slices to RO indeed supports the notion that NMDA receptor
inhibition inﬂuences the molecular properties of this neu-
rotransmission system. Our results are in line with several
reports showing that the number of NMDA receptors, the
composition of their subunits and their postsynaptic linkers
can be altered after the administration of NMDA receptor
antagonists, including MK-801, ethanol, and phencyclidine
[24, 35–37]. It is of interest that according to the present
investigation, a signiﬁcant increase in the levels of NR1
and NR2B subunits was observed after the blockade of
NR2A-containing receptors, suggesting that the molecular
mechanism underlying NVP-induced Tau phosphorylation
in acute hippocampal slices might involve NMDA receptor
enrichment at the membrane surface. We do not know the
mechanism through which inhibition of NR2A-containing
NMDA receptors could up-regulate NR1/NR2B subunits
on hippocampal membranes. It is worth mentioning, how-
ever, that the surface expression and mobility of NR2A-
and NR2B-containing receptors are diﬀerentially regulated,
depending on scaﬀolding proteins interacting with the NR2
subunits. For instance, surface NR2B-containing NMDA
r e c e p t o r sa p p e a rt ob em o r em o b i l ew i t h i nn e u r o n s ,p o s -
sibly due in part to preferential interaction with synapse-
associated protein 102 (SAP-102), over postsynaptic protein
95 [38]. Indeed, it remains to be determined whether
NR1/NR2B receptor enrichment at the membrane surface
depends on higher expression of NR2B subunit-SAP-102
complexes after NVP application. It is interesting that
calcium mobilization is one of the consequences of NMDA
receptor inactivation by global antagonists through mech-
anisms involving the incorporation of calcium-permeable
AMPA receptors in neuronal membranes [10]. This issue
needs to be further explored, but the present investigation
strongly indicates that this scenario does not account for the
capacity of NVP to induce Tau phosphorylation.
4.1. Summary and Conclusions. The current study argues
that tonic activation of NR2A-containing NMDA receptors
is required to limit Tau hyperphosphorylation at its Ser199
site. It is indeed premature to speculate on the functional
signiﬁcance of this eﬀect, and the next challenge resulting
from our observation will be to directly demonstrate that
such increases in Tau phosphorylation may engage alter-
ations in hippocampal functions. As reported previously,
Tau predominantly localizes to neuronal axons where it
modulates the stability and assembly of microtubules [39,
40]. In so doing, Tau generates a partially stable, but still
dynamic, state in microtubules that is important for axonal
growth and eﬀective axonal transport [41]. In addition to
binding microtubules, some but not all studies provide
evidence that Tau can interact, either directly or indirectly,
with actin and aﬀect actin polymerization as well as the
interaction of actin ﬁlaments with microtubules [42, 43].
Furthermore, Tau appears to interact with the plasma
membrane and with several proteins involved in signal
transduction [44–52]. From a pathological perspective, Tau
dysfunctionresultingfrombiochemicaldefects(i.e.,aberrant
phosphorylation, truncation, and glycosylation) has been
proposed to be an important factor contributing to the
initiation and development of several neuropathological
conditions such as AD [16, 28, 53–56]. Thus, the fact that
NR2A subunits are down regulated [57], coupled with the
observation that hyperphosphorylation of Tau at Ser199
is present in the early stage of this disease [54], strongly
suggests that the eﬀect reported here may have interesting
implications for understanding the mechanisms of AD.
Collectively, our ﬁndings suggest that drugs acting as NMDA
receptor antagonists could increase Ca2+ inﬂux through
inhibition of NR2A-containing receptors and enrichment
of NR1/NR2B subunits. Such a change in receptor subunit
composition could theoretically favour the appearance of
adverse neuropathological eﬀects [58], and should be eval-
uated further.
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